Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Danaher (DHR) stock in plain English

Free brief · no signupStart here
DHRPublished Nov 9, 2026
Danaher Corp
Healthcare · Diagnostics & Research
Sells instruments, consumables, and software used for medical diagnostic testing and biopharmaceutical drug production.
Assets:
Cytiva and PallProduce filtration and purification hardware for biomanufacturing plants worldwide
Cepheid diagnosticsMaintains an active base of over 50,000 automated testing systems
63,000 employeesStaff research, manufacturing, and commercial offices in dozens of countries
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

63
OPS ScoreOperating finances
Latest quote
-0.45%$227.56
$160.10B
37.3×
$25.62B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 09, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was DHR. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Danaher (DHR) do?

Danaher Corp (DHR) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells instruments, consumables, and software used for medical diagnostic testing and biopharmaceutical drug production. It buys life sciences and diagnostics toolmakers, then applies its shared operational system to cut waste. It is worth $160.10B on the market and sold $25.62B over the last year.

Market cap
$160.10B
P/E ratio
37.3×
Annual sales
$25.62B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 09, 2026

Brands and businesses behind DHR

  • Cytiva: Sells filtration hardware, chromatography resins, and cell culture media to commercial drugmakers.
  • Cepheid: Manufactures automated molecular diagnostic instruments and single-use test cartridges for clinical labs.
  • Beckman Coulter: Supplies automated clinical chemistry and hematology analyzers along with reagent tests to hospitals.
  • Pall Corporation: Produces industrial filtration membranes and fluid separation assemblies for medical and aerospace customers.
  • Leica Microsystems: Builds optical microscopes and imaging platforms used in surgical suites and scientific research.
  • Sciex: Develops mass spectrometry instruments and software used to quantify complex chemical samples.

DHR’s flags, in plain English

Each flag is a number from Danaher’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 09, 2026.

Wide Gross Margin

Gross margin of 58.9% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 1.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 52% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Priced for Perfection

Priced at 37.3 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about DHR

How big is Danaher?

Danaher’s market cap is $160.10B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $25.62B: what customers paid the company over the last year, before any costs.

What is DHR’s P/E ratio?

DHR’s P/E ratio is 37.3×. Investors pay about 37.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with DHR?

A prolonged slowdown in venture funding for biotechnology firms currently suppresses customer orders for bioprocessing equipment and single-use supplies. That is one risk on Danaher’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Danaher’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. DHR’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card